Profile data is unavailable for this security.
About the company
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
- Revenue in INR (TTM)42.09bn
- Net income in INR8.16bn
- Incorporated1979
- Employees7.84k
- LocationAjanta Pharma LtdAjanta House,, Charkop, Kandivli West,MUMBAI 400067IndiaIND
- Phone+91 2 266061000
- Fax+91 2 266061200
- Websitehttps://www.ajantapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi India Ltd | 28.47bn | 5.49bn | 153.74bn | 2.17k | 28.00 | -- | 26.10 | 5.40 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Concord Biotech Ltd | 10.17bn | 3.08bn | 178.12bn | 1.38k | 57.84 | 11.67 | 49.25 | 17.52 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | 7,385,180.00 | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 179.32bn | 940.00 | 111.02 | 25.19 | 101.62 | 13.84 | 64.60 | 64.60 | 518.21 | 284.77 | 1.26 | 2.84 | 9.79 | 13,782,230.00 | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 54.64 | 12.47 | 10.27 | 1.97 | 141.26 | 0.0064 | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Piramal Pharma Ltd | 83.73bn | 277.60m | 219.71bn | 6.72k | 790.20 | -- | 28.19 | 2.62 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Suven Pharmaceuticals Ltd | 10.51bn | 3.00bn | 236.35bn | 1.05k | 78.64 | 11.53 | 66.60 | 22.48 | 11.81 | 11.81 | 41.34 | 80.56 | 0.4983 | 1.64 | 8.58 | 9,993,856.00 | 14.23 | 23.17 | 15.19 | 26.20 | 57.34 | 58.85 | 28.56 | 33.21 | 9.64 | 47.59 | 0.0307 | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Natco Pharma Ltd. | 39.99bn | 13.88bn | 239.05bn | 3.98k | 17.27 | 4.08 | 15.18 | 5.98 | 77.30 | 77.30 | 222.76 | 326.99 | 0.6366 | 0.9929 | 3.91 | -- | 22.10 | 12.33 | 25.46 | 14.25 | 82.08 | 76.47 | 34.72 | 25.16 | 3.42 | 81.49 | 0.0596 | -- | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | -- |
| Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 239.09bn | 14.86k | 38.81 | 4.96 | 26.91 | 3.84 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | 4,192,105.00 | 9.75 | 10.72 | 12.92 | 14.25 | 72.46 | 65.98 | 9.89 | 12.47 | 0.9863 | 11.56 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Pfizer Ltd | 21.93bn | 5.51bn | 239.87bn | 1.70k | 43.51 | 6.67 | 39.09 | 10.94 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Laurus Labs Ltd | 50.54bn | 1.48bn | 242.11bn | 6.01k | 163.72 | -- | 43.80 | 4.79 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Emcure Pharmaceuticals Ltd | 66.58bn | 4.98bn | 245.33bn | 11.15k | 49.24 | 8.31 | 29.21 | 3.68 | 26.35 | 26.35 | 352.11 | 156.12 | 0.9197 | 1.70 | 3.78 | 5,973,669.00 | 7.29 | 7.14 | 13.30 | 13.93 | 61.02 | 59.29 | 7.92 | 7.81 | 0.8319 | 5.79 | 0.4279 | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 34.84bn | 5.53bn | 292.53bn | 5.10k | 54.01 | 10.01 | 42.34 | 8.40 | 34.90 | 34.90 | 219.88 | 188.37 | 0.9232 | 2.50 | 5.52 | -- | 14.64 | 15.77 | 18.04 | 18.89 | 66.07 | 61.18 | 15.86 | 16.06 | 1.56 | 17.11 | 0.1144 | 32.31 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Ajanta Pharma Ltd | 42.09bn | 8.16bn | 299.94bn | 7.84k | 37.07 | 8.48 | 31.52 | 7.13 | 64.79 | 64.79 | 334.10 | 283.31 | 0.9034 | 1.30 | 3.65 | 5,365,515.00 | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.22 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| IPCA Laboratories Ltd | 77.07bn | 5.47bn | 326.09bn | 17.34k | 59.57 | 5.15 | 36.79 | 4.23 | 21.58 | 21.58 | 303.80 | 249.59 | 0.7814 | 1.20 | 5.64 | 4,446,155.00 | 5.37 | 10.33 | 7.51 | 13.52 | 66.58 | 59.16 | 6.87 | 12.25 | 1.28 | 13.12 | 0.1569 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| Gland Pharma Ltd | 56.65bn | 7.72bn | 332.24bn | 4.59k | 43.01 | 3.81 | 29.74 | 5.87 | 46.89 | 46.89 | 343.86 | 529.65 | 0.5828 | 1.21 | 4.12 | -- | 7.95 | 13.23 | 8.92 | 14.56 | 61.64 | 55.88 | 13.64 | 22.92 | 2.85 | 37.73 | 0.0409 | -- | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Glenmark Pharmaceuticals Ltd | 118.13bn | -18.99bn | 405.90bn | 15.56k | -- | 5.17 | -- | 3.44 | -67.28 | -53.21 | 418.40 | 278.11 | 0.7004 | 1.81 | 4.28 | -- | -10.86 | 1.02 | -15.92 | 1.43 | 62.64 | 61.27 | -15.50 | 1.43 | 0.8447 | 1.19 | 0.1356 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
Data as of Jul 26 2024. Currency figures normalised to Ajanta Pharma Ltd's reporting currency: Indian Rupee INR
14.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UTI Asset Management Co. Ltd. (Investment Management)as of 30 Jun 2024 | 4.16m | 3.31% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Jun 2024 | 3.79m | 3.01% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 1.63m | 1.29% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Jun 2024 | 1.55m | 1.23% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2024 | 1.23m | 0.97% |
| White Oak Capital Partners Pte Ltd.as of 30 Jun 2023 | 1.18m | 0.94% |
| Canara Robeco Asset Management Co. Ltd.as of 30 Jun 2024 | 1.14m | 0.90% |
| Tata AIA Life Insurance Co. Ltd.as of 30 Jun 2024 | 1.04m | 0.83% |
| Invesco Asset Management (India) Pvt Ltd.as of 30 Jun 2024 | 1.00m | 0.80% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Jun 2024 | 928.55k | 0.74% |
More ▼
Data from 30 Jun 2023 - 18 Jul 2024Source: FactSet Research Systems Inc.
